Cargando…

Identification of Aloe-derived natural products as prospective lead scaffolds for SARS-CoV-2 main protease (M(pro)) inhibitors

In the past two years, the COVID-19 pandemic has caused over 5 million deaths and 250 million infections worldwide. Despite successful vaccination efforts and emergency approval of small molecule therapies, a diverse range of antivirals is still needed to combat the inevitable resistance that will a...

Descripción completa

Detalles Bibliográficos
Autores principales: Hicks, Emily G., Kandel, Sylvie E., Lampe, Jed N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9004148/
https://www.ncbi.nlm.nih.gov/pubmed/35427739
http://dx.doi.org/10.1016/j.bmcl.2022.128732
_version_ 1784686228697776128
author Hicks, Emily G.
Kandel, Sylvie E.
Lampe, Jed N.
author_facet Hicks, Emily G.
Kandel, Sylvie E.
Lampe, Jed N.
author_sort Hicks, Emily G.
collection PubMed
description In the past two years, the COVID-19 pandemic has caused over 5 million deaths and 250 million infections worldwide. Despite successful vaccination efforts and emergency approval of small molecule therapies, a diverse range of antivirals is still needed to combat the inevitable resistance that will arise from new SARS-CoV-2 variants. The main protease of SARS-CoV-2 (M(pro)) is an attractive drug target due to the clinical success of protease inhibitors against other viruses, such as HIV and HCV. However, in order to combat resistance, various chemical scaffolds need to be identified that have the potential to be developed into potent inhibitors. To this end, we screened a high-content protease inhibitor library against M(pro)in vitro, in order to identify structurally diverse compounds that could be further developed into antiviral leads. Our high-content screening efforts retrieved 27 hits each with > 50% inhibition in our M(pro) FRET assay. Of these, four of the top inhibitor compounds were chosen for follow-up due to their potency and drugability (Lipinski’s rules of five criteria): anacardic acid, aloesin, aloeresin D, and TCID. Further analysis via dose response curves revealed IC(50) values of 6.8 μM, 38.9 μM, 125.3 μM, and 138.0 μM for each compound, respectively. Molecular docking studies demonstrated that the four inhibitors bound at the catalytic active site of M(pro) with varying binding energies (-7.5 to −5.6 kcal/mol). Furthermore, M(pro) FRET assay kinetic studies demonstrated that M(pro) catalysis is better represented by a sigmoidal Hill model than the standard Michaelis-Menten hyperbola, indicating substantial cooperativity of the active enzyme dimer. This result suggests that the dimerization interface could be an attractive target for allosteric inhibitors. In conclusion, we identified two closely-related natural product compounds from the Aloe plant (aloesin and aloeresin D) that may serve as novel scaffolds for M(pro) inhibitor design and additionally confirmed the strongly cooperative kinetics of M(pro) proteolysis. These results further advance our knowledge of structure–function relationships in M(pro) and offer new molecular scaffolds for inhibitor design.
format Online
Article
Text
id pubmed-9004148
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-90041482022-04-12 Identification of Aloe-derived natural products as prospective lead scaffolds for SARS-CoV-2 main protease (M(pro)) inhibitors Hicks, Emily G. Kandel, Sylvie E. Lampe, Jed N. Bioorg Med Chem Lett Article In the past two years, the COVID-19 pandemic has caused over 5 million deaths and 250 million infections worldwide. Despite successful vaccination efforts and emergency approval of small molecule therapies, a diverse range of antivirals is still needed to combat the inevitable resistance that will arise from new SARS-CoV-2 variants. The main protease of SARS-CoV-2 (M(pro)) is an attractive drug target due to the clinical success of protease inhibitors against other viruses, such as HIV and HCV. However, in order to combat resistance, various chemical scaffolds need to be identified that have the potential to be developed into potent inhibitors. To this end, we screened a high-content protease inhibitor library against M(pro)in vitro, in order to identify structurally diverse compounds that could be further developed into antiviral leads. Our high-content screening efforts retrieved 27 hits each with > 50% inhibition in our M(pro) FRET assay. Of these, four of the top inhibitor compounds were chosen for follow-up due to their potency and drugability (Lipinski’s rules of five criteria): anacardic acid, aloesin, aloeresin D, and TCID. Further analysis via dose response curves revealed IC(50) values of 6.8 μM, 38.9 μM, 125.3 μM, and 138.0 μM for each compound, respectively. Molecular docking studies demonstrated that the four inhibitors bound at the catalytic active site of M(pro) with varying binding energies (-7.5 to −5.6 kcal/mol). Furthermore, M(pro) FRET assay kinetic studies demonstrated that M(pro) catalysis is better represented by a sigmoidal Hill model than the standard Michaelis-Menten hyperbola, indicating substantial cooperativity of the active enzyme dimer. This result suggests that the dimerization interface could be an attractive target for allosteric inhibitors. In conclusion, we identified two closely-related natural product compounds from the Aloe plant (aloesin and aloeresin D) that may serve as novel scaffolds for M(pro) inhibitor design and additionally confirmed the strongly cooperative kinetics of M(pro) proteolysis. These results further advance our knowledge of structure–function relationships in M(pro) and offer new molecular scaffolds for inhibitor design. Elsevier Ltd. 2022-06-15 2022-04-12 /pmc/articles/PMC9004148/ /pubmed/35427739 http://dx.doi.org/10.1016/j.bmcl.2022.128732 Text en © 2022 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Hicks, Emily G.
Kandel, Sylvie E.
Lampe, Jed N.
Identification of Aloe-derived natural products as prospective lead scaffolds for SARS-CoV-2 main protease (M(pro)) inhibitors
title Identification of Aloe-derived natural products as prospective lead scaffolds for SARS-CoV-2 main protease (M(pro)) inhibitors
title_full Identification of Aloe-derived natural products as prospective lead scaffolds for SARS-CoV-2 main protease (M(pro)) inhibitors
title_fullStr Identification of Aloe-derived natural products as prospective lead scaffolds for SARS-CoV-2 main protease (M(pro)) inhibitors
title_full_unstemmed Identification of Aloe-derived natural products as prospective lead scaffolds for SARS-CoV-2 main protease (M(pro)) inhibitors
title_short Identification of Aloe-derived natural products as prospective lead scaffolds for SARS-CoV-2 main protease (M(pro)) inhibitors
title_sort identification of aloe-derived natural products as prospective lead scaffolds for sars-cov-2 main protease (m(pro)) inhibitors
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9004148/
https://www.ncbi.nlm.nih.gov/pubmed/35427739
http://dx.doi.org/10.1016/j.bmcl.2022.128732
work_keys_str_mv AT hicksemilyg identificationofaloederivednaturalproductsasprospectiveleadscaffoldsforsarscov2mainproteasemproinhibitors
AT kandelsylviee identificationofaloederivednaturalproductsasprospectiveleadscaffoldsforsarscov2mainproteasemproinhibitors
AT lampejedn identificationofaloederivednaturalproductsasprospectiveleadscaffoldsforsarscov2mainproteasemproinhibitors